Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Closed Viral Vector Manufacturing Platforms Market Size And Revenue Outlook Through 2030
The closed viral vector manufacturing platforms market size has seen rapid growth recently. It is forecast to expand from $1.96 billion in 2025 to $2.22 billion in 2026, at a compound annual growth rate (CAGR) of 13.4%. The expansion observed in prior periods can be attributed to an increase in gene therapy clinical trials, greater use of viral vectors in vaccine creation, the development of cell and gene therapy research initiatives, an increased regulatory emphasis on sterile production, and the early implementation of closed processing technologies.
The closed viral vector manufacturing platforms market is projected to experience substantial growth in the coming years. It is expected to reach $3.63 billion by 2030, progressing at a compound annual growth rate (CAGR) of 13.1%. This expansion during the forecast period can be attributed to the increasing commercialization of gene therapies, a rising demand for large-scale viral vector supply, growing investments in advanced biomanufacturing infrastructure, the expansion of contract manufacturing capacity, and an increasing focus on process standardization and automation. Significant trends anticipated during this period include the wider adoption of fully closed and automated production systems, a heightened demand for scalable viral vector manufacturing platforms, the increasing integration of single-use and modular components, the expansion of end-to-end closed processing workflows, and an enhanced focus on regulatory compliance and contamination control.
Get A Free Sample Report With In-Depth Market Insights:
Closed Viral Vector Manufacturing Platforms Market Growth Backed By Core Demand Fundamentals
The increasing number of clinical trials is anticipated to drive the expansion of the closed viral vector manufacturing platforms market in the future. Clinical trials are meticulously planned human studies conducted to evaluate the safety, effectiveness, and proper application of new medical therapies or interventions. The demand for these trials is growing due to an escalating need for innovative therapies, as the rising prevalence of chronic and complex diseases necessitates the development and testing of new drugs and treatments to address unmet medical needs. Closed viral vector manufacturing platforms support clinical trials by ensuring the consistent and sterile production of viral vectors, thereby guaranteeing the safety and reliability of the therapies under investigation. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the total number of industry-sponsored clinical trials launched in the UK increased from 411 in 2022 to 426 in 2023. Therefore, the expanding volume of clinical trials is fueling the growth of the closed viral vector manufacturing platforms market.
Closed Viral Vector Manufacturing Platforms Market Segment Analysis: What Are The Core Market Categories?
The closed viral vector manufacturing platforms market covered in this report is segmented –
1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types
2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish
3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users
Subsegments:
1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA
2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors
3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors
4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)
5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors
6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors
Closed Viral Vector Manufacturing Platforms Market Growth Trends Reshaping The Competitive Landscape
Major companies in the closed viral vector manufacturing platforms market are concentrating on developing advanced solutions, such as nitro controllers, to prevent nitrogen-induced stress or toxicity in cell cultures. These nitro controllers are devices or systems used to monitor and regulate nitrogen levels or reactive nitrogen species in bioprocesses, ensuring optimal conditions for cell growth and product formation. For instance, in May 2025, Univercells Technologies, a Belgium-based biotechnology company, introduced the scale-X nitro controller. It is a compact and economical system engineered for large-scale viral vector and vaccine production. This system is compatible with 200 m² and 600 m² scale-X nitro bioreactors, supporting both adherent and suspension cell cultures. The system enables efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Additionally, it allows rapid scale-up, facilitating the transition from research and development to commercial manufacturing within eight months.
Closed Viral Vector Manufacturing Platforms Market Top Companies Driving Competitive Growth
Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.
View The Full Closed Viral Vector Manufacturing Platforms Market Report:
Closed Viral Vector Manufacturing Platforms Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model